It is already known that MGMT methylation is associated with better outcomes in both IDH mutant and IDH wildtype GBM [27, 28], although it only constitutes a predictive biomarker for the benefit to temozolomide chemotherapy and not to radiotherapy in patients with GBM-IDH wildtype [25]. Here, IDH1 is linked to glioblastoma.